Abstract
We have studied whether it is possible to discriminate responders to tacrine treatment from patients nonresponsive to tacrine in Alzheimer's disease. The results indicate that mildly demented patients will most likely gain a benefit of tacrine treatment. Neuropsychological tests on attention and working memory after a single dose of tacrine might be useful as well as a single dose pharmaco-EEG in discriminating responders to treatment.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Alzheimer Disease / diagnosis
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / metabolism
-
Attention / drug effects
-
Biogenic Monoamines / cerebrospinal fluid
-
Biogenic Monoamines / metabolism
-
Cholinesterase Inhibitors / pharmacology*
-
Cholinesterase Inhibitors / therapeutic use*
-
Female
-
Humans
-
Male
-
Memory / drug effects*
-
Neuropsychological Tests
-
Somatostatin / cerebrospinal fluid
-
Somatostatin / metabolism
-
Tacrine / pharmacology*
-
Tacrine / therapeutic use*
-
Treatment Outcome
Substances
-
Biogenic Monoamines
-
Cholinesterase Inhibitors
-
Tacrine
-
Somatostatin